Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by retiredcopon Jun 17, 2020 10:10am
262 Views
Post# 31159607

Needed some clarification

Needed some clarification When I saw todays announcement I initally was not that impressed on the 99.9 % and 99.5 % accuracy. Previously I was convinved that 100%  and 99.9 % was going to be almost necessary for a valid test. Clarification gave me a better understanding of what was happening.

First thing is that PMN's test is based on SPR and not ELISA . It appears as though we are the only one out there doing SPR development. I now know that SPR are is more difficult but in the end it is more accurate, more stable and will be the best way to know if the antibodies present will protect the host against the virus. 
 
"But the key step in development of a ‘best in class’ test is to create an assay that not only detects the presence of antibodies specific for the SARS CoV-2 virus but importantly, also allows to determine whether or not the detected antibodies have neutralizing activity, potentially conferring protection from COVID-19 

The vaccines are developing at a unprecidented pace and PMN's test will be very important when it comes to getting a fast evaluation, capable of high volumme testing to see if the vaccine is working. There is stil alot of work to do but I feel that its already well underway. I am of the opinion that this newsrelease is not real time and that we could be looking at a picture that has happened awhile back and the next stages of development are well underway. We will hear more and possibly get some opinions from otrher experts in the field of test development. Like usual,  unless you are scientist this reveal will not mean as much ... but as I say that the market seems to have reacted to what was stated. It was also clear to me that there will be more info coming out in the near future and it appears to deal with covid...     
Bullboard Posts